The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. - Wikidata - wikimedia - TriplyDB

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

http://www.wikidata.org/entity/Q37217739

about

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs Organ-wide 3D-imaging and topological analysis of the continuous microvascular network in a murine lymph node Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.ABC transporters in CSCs membranes as a novel target for treating tumor relapse.Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

P2860

Q26774750-9943A520-A0CF-47ED-86DC-39CCE6FC04E7 Q27306661-AD075E6E-A09D-4272-848C-82102CEAC70E Q33420436-9F2AFE22-44D4-403A-85F8-66F30FFE80D7 Q33770742-D9C6CF4F-FA6B-4AA2-86C7-BC00B38B2544 Q33879326-D41424B8-DFD0-4D5C-AFAC-25E25273FB0F Q36212847-83CAF43E-2686-45BF-B4A4-E3FF96A76023 Q38177279-B83FDD3A-318C-47F1-8F94-B50940914A79 Q38806173-0166DE48-F9FC-4668-8B84-A825BC05828B Q50103495-488A1FAA-575D-4E60-AFF3-9CDDAFB71470 Q57073801-8C0D7015-353B-4D82-905F-0DE427378448

P2860

The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.

http://www.wikidata.org/entity/Q37217739

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@en

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@nl

type

label

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@en

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@nl

prefLabel

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@en

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@nl

P1433

Q37217739-E798848A-6C53-409C-B40D-504D6C5BEC9B

P1476

Q37217739-A8B47F26-3C49-4CDF-9366-EECC5BD1CCC4

P2093

Q37217739-0C1834B3-B32E-4745-BC5C-F03EFD6A0C83

Q37217739-0ED61BCE-8A8C-4D97-8D68-31987718BE7B

Q37217739-2095A4CF-0BAF-4CE8-B962-3E6470B7C649

Q37217739-722DED7E-F4F8-4BE4-B2CD-3082B136F55B

Q37217739-AB91F76E-4960-46BE-83C3-4C7BEB14A27E

P2860

Q37217739-00DF4AFD-122E-4B35-95F5-E3A10816E0F9

Q37217739-0E92E165-B3BA-417E-A25B-0F3F0C4EFA15

Q37217739-1E48C705-771E-4AD2-AF34-3ACEFD76E258

Q37217739-2495FD20-D2A5-4ED5-86CE-34E418210DF1

Q37217739-33AE8C36-BFB3-40D8-918E-CC72D5A05814

Q37217739-3F62C34B-6CA3-4587-A626-4DF436B561B4

Q37217739-430B50E3-DD5D-495C-AA5F-567A10E79157

Q37217739-4BE6112A-3675-4566-BE22-524FAB483D16

Q37217739-51AFECFC-D0FE-4CB2-AEF3-FBE3D9E165F4

Q37217739-52C9CB27-CE03-4D4B-BE75-08C55A5C4C93

P304

Q37217739-3548708D-4B5E-4E5D-B980-3D24A0F59032

P31

Q37217739-65DC418C-7278-4646-B3A5-D5A889D3F7EF

P356

Q37217739-62A2E9F9-5F89-4E2F-898E-4FE55CABCC8A

P478

Q37217739-E5D05B8C-5694-4051-9A8D-4F4E002CFAEC

P50

Q37217739-15121B52-0350-455E-B15B-F5DDD1EC32EF

Q37217739-5A8EFD6B-57AE-4E88-AFB9-6F9365C15812

P577

Q37217739-096165AC-4E6E-4D56-B856-A19179BB4321

P5875

Q37217739-0318FBA7-49B6-4556-816A-657F130EEE1D

P698

Q37217739-5C5AB4FC-27C8-49AC-A93D-184EFFA2C45E

P921

Q37217739-6B0EBC9C-F793-461E-BDE6-725835A33879

P932

Q37217739-06D936D7-FA92-4F5A-B566-3C7FE78954CC

P356

FONC.2013.00263

P1433

Frontiers in Oncology

P1476

The Role of Bystander Effects ...... oxia-Activated Prodrug PR-104.

@en

P2093

Annika Foehrenbacher

http://www.w3.org/2001/XMLSchema#string

Kashyap Patel

http://www.w3.org/2001/XMLSchema#string

Kevin O Hicks

http://www.w3.org/2001/XMLSchema#string

Maria R Abbattista

http://www.w3.org/2001/XMLSchema#string

William R Wilson

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting hypoxia in cancer therapy

Intra-tumour heterogeneity: a looking glass for cancer?

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

Structural adaptation and heterogeneity of normal and tumor microvascular networks.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration--time product.

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

Suicide gene therapy in cancer: where do we stand now?

Microvascular permeability of normal and neoplastic tissues.

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer.

P304

263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2013.00263

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Timothy W Secomb

P577

2013-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257600458

http://www.w3.org/2001/XMLSchema#string

P698

24109591

http://www.w3.org/2001/XMLSchema#string

P921

P932

3791487

http://www.w3.org/2001/XMLSchema#string